BofA’s Hartnett says concentrated U.S. stock returns are likely to persist
CAMBRIDGE, MA—Relay Therapeutics, Inc. (NASDAQ:RLAY), a biotech company currently valued at $575 million, recently reported that Brian Adams, the company’s Chief Legal Officer, sold shares totaling $44,040. The transactions took place on April 28 and April 30, 2025. According to InvestingPro analysis, the stock is currently trading slightly below its Fair Value, with a FAIR financial health score.
On April 28, Adams sold 1,644 shares at a price of $3.17 each, while on April 30, he sold an additional 12,943 shares at $3 per share. These sales were made to cover the income tax withholding obligations related to the vesting of restricted stock units (RSUs), as per company policy. Following these transactions, Adams retains ownership of 391,385 shares, including 192,510 shares underlying RSUs. The stock has shown notable volatility, trading between $1.77 and $10.72 over the past 52 weeks. For deeper insights into insider trading patterns and comprehensive analysis, access the full RLAY research report on InvestingPro, which covers over 1,400 US stocks.
In other recent news, Relay Therapeutics has been the focus of significant developments. Citizens JMP has revised its price target for Relay Therapeutics, reducing it from $21.00 to $12.00, though it maintained a Market Outperform rating. This adjustment is linked to a shift in dosage during the transition from phase 2 to phase 3 trials of Relay’s drug candidate. Despite the surprise change in dosage, Citizens JMP’s analyst remains optimistic due to new pharmacokinetic and pharmacodynamic data that support the dose reduction, potentially improving patient tolerability. Relay Therapeutics is working to replace the current treatment combination in second-line treatment for metastatic breast cancer patients who have undergone CDK4/6 inhibition. The company’s ReDiscover phase 2 trial has shown promising results, with RLY-2608 demonstrating significant progression-free survival improvements. Specifically, the trial reported a 9.2-month progression-free survival across all patients and 11.4 months in those with kinase domain mutations. These findings suggest that RLY-2608 could offer best-in-class efficacy and safety in its treatment setting.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.